Baseline Clinical Characteristics of Patients Recruited into the Assessment of Treatment with Lisinopril and Survival Study
- 1 March 1999
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 1 (1) , 73-79
Abstract
Background: The beneficial effect of ACE inhibitors on mortality has been established in a series of trials. However, in clinical practice, ACE inhibitors are commonly administered in doses much lower than those shown to be effective in the landmark trials. Aims: This report describes the baseline characteristics of the patients recruited into the ATLAS study by age and gender sub-groups. Methods: The ATLAS study compared the effects of ‘low’ dose (2.5–5.0 mg/day) to ‘high’ dose (32.5–55.0 mg/day) lisinopril in a double-blind study of 5164 patients with moderate to severe heart failure and left ventricular ejection fraction < 30% during a mean follow-up period of 46 months. The primary end-point was all cause mortality and the principal secondary end-point a composite of all-cause hospitalisation or all-cause mortality. Results: Among patients with heart failure selected for the presence of left ventricular systolic function there were few differences among age groups or between genders. Older patients were not so heavy, were more likely to have ischaemic heart disease, hypertension and atrial fibrillation contributing to their heart failure and had a higher blood urea. Women were not so heavy as men. Age and gender had no major influence on mean ejection fraction or baseline treatment in the ATLAS study. Conclusions: Weight and renal function may alter the plasma concentration of any given dose of an ACE inhibitor. Potential interactions between dose of lisinopril, weight and renal function will be explored after the study is completed.Keywords
This publication has 14 references indexed in Scilit:
- Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparisonEuropean Heart Journal, 1998
- Screening For Left Ventricular Dysfunction and Chronic Heart FailureDisease Management and Health Outcomes, 1997
- ACE inhibitors for heart failure: a question of doseHeart, 1994
- Patient Characteristics in Cases of Chronic Severe Heart Failure with Different Degrees of Left Ventricular Systolic DysfunctionCardiology, 1994
- Survival of Elderly Men with Congestive Heart FailureAge and Ageing, 1992
- A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart FailureNew England Journal of Medicine, 1991
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- Epidemiology of heart failureAmerican Heart Journal, 1991
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- The cardiomyopathies.Heart, 1972